set stori meantim like
take breather downgrad neutral
think edward set stori revenu grow
ep investor like look forward
releas edward medtron risk tavr trial march
compani transcathet mitral tricuspid repair program
begin ramp meaning contribut top-lin perform first
time therefor look like transit year albeit project top-
line bottom-lin growth see upsid ep guidanc consensu
forecast meaning top-lin beat may harder come tavr
market slow amidst absenc catalyst prior risk data
clear still bullish edward outlook think investor want
revisit share get closer tavr-driven revenu beat less
like meaning mitral tricuspid catalyst see
share take breather step sidelin neutral rate
see global tavr guidanc growth reason
conserv street consensu therefor think upsid
consensu tavr estim less like edward show upsid
yoy growth market first need stabil last quarter edward
us tavr busi slow yoy
first time edward guidanc impli
growth think growth stabil reach low-
doubl digit model there like
catalyst reacceler risk growth doesnt stabil
put upper end manag tavr guidanc risk
think top-lin upsid less like view ep guidanc
street consensu immin beatabl see upsid
street margin tax assumpt anticip upward ep revis
cours year
beyond health tavr market view edward emerg
pipelin mitral tricuspid repair key multipl expans
decemb analyst meet edward forecast market mitral tricuspid
therapi grow forecast seem
reason think abbott mitraclip track reach
alon model edward
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
edward pipelin actual fairli robust five novel transcathet repair
product potenti launch europ next month
start cardioband mr direct annuloplasti approach mitral valv repair
acquir edward valtech transact cardioband mr launch
europ follow edward refin train program build-out
mitral clinic support team model cardioband gener sale
rise includ late us approv cardioband mr us
pivot trial activ enrol expect complet enrol
follow-up expect cardioband tr receiv ce
mark follow pascal tmv repair system
follow complet follow-up clasp decemb
close harpoon medic acquisit edward also plan launch
devic europ us launch line european approv
immin expect edward begin train launch
product sale grow final edward
place forma tricuspid spacer program hold better enhanc devic
procedur resum implant later
ep edward start get credit pipelin
view recogn even limit contribut mitral tricuspid
edward abl grow top line warrant multipl expans
edward like need either stronger tavr market current street
expect increas enthusiasm mitral tricuspid pipelin despit
limit number potenti catalyst mileston watch includ
follow-up cardioband tr earli feasibl trial like pcr
may result clasp pascal ce mark trial like tct
septemb edward test next-gener cardiaq valv deliveri
system year-end price target unchang valu edward
ep line stock current valuat earn
dont see catalyst move multipl either way
invest thesi valuat risk
edward set stori revenu grow
ep investor like look forward
releas edward medtron risk tavr trial march
compani transcathet mitral tricuspid repair program
begin ramp meaning contribut top-lin perform first
time therefor transit year albeit project top-lin
bottom-lin growth come risk howev tavr market
slow last sever quarter like slow get
risk trial fulli expect posit therefor catalyst
absent top-lin upsid meaning pipelin catalyst next month
think edward shape stori investor want
revisit later year downgrad neutral
dec price target valu ew share ep
repres signific premium current large-cap med-tech
averag cash ep believ premium justifi given
edward differenti outlook top bottom line
risk rate price
upsid risk rate includ better-than-expect tavr growth
competitor pipelin product failur better-than-expect critic
perform favor chang tavr procedur reimburs
downsid risk rate includ increas competit us
clinic trial result setback compani transcathet mitral program
edward lifesci summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
